MedTrace Logo

Group B Strep Correlates of Protection Study

NCT06431217 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17842

Last updated 2024-12-11

No results posted yet for this study

Summary

Streptococcus agalactiae or Group B Streptococcus (GBS) is a leading cause of neonatal sepsis in developed and developing countries.

The study aims to bolster the evidence base of establishing a sero-correlate of protection against invasive GBS disease in infants.

These sero-correlates of protection will be used to study the effectiveness of GBS vaccine against invasive disease.

Conditions

Sponsors & Collaborators

  • University of KwaZulu

    collaborator OTHER

  • University of Stellenbosch

    collaborator OTHER

  • University of Pretoria

    collaborator OTHER

  • University of Cape Town

    collaborator OTHER

  • University of Witwatersrand, South Africa

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06431217 on ClinicalTrials.gov